Therapeutic perspectives of Eph-ephrin system modulation

Drug Discovery Today

Volumn 19, Issue 5, 2014, Pages 661-669

  Tognolini, Massimiliano ^a   Hassan Mohamed, Iftiin ^a   Giorgio, Carmine ^a   Zanotti, Ilaria ^a   Lodola, Alessio ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; EPHRIN; EPHRIN RECEPTOR; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

AMYOTROPHIC LATERAL SCLEROSIS; CANCER TISSUE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; EMBRYO DEVELOPMENT; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERIOSCLEROSIS; ARTHRITIS; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; ARTERIOSCLEROSIS; ARTHRITIS; EPHRINS; HUMANS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RECEPTORS, EPH FAMILY;

EID: 84901497370     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.11.017     Document Type: Review

References (81)

1. J-P. Himanen, and D.B. Nikolov Eph signaling: a structural view Trends Neurosci. 26 2003 46 51
2. J-P. Himanen et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling Nat. Neurosci. 7 2004 501 509
3. E.B. Pasquale Eph-ephrin bidirectional signaling in physiology and disease Cell 133 2008 38 52
4. C. Kosinski et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors Proc. Natl. Acad. Sci. U.S.A. 104 2007 15418 15423
5. N. Prevost et al. Contact-dependent signaling during the late events of platelet activation J. Thromb. Haemost. 1 2003 1613 1627
6. I. Konstantinova et al. EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets Cell 129 2007 359 370
7. J.J. Muñoz et al. Eph/Ephrin-mediated interactions in the thymus Neuroimmunomodulation 18 2011 271 280
8. A.I. Ivanov et al. Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats Physiol. Genomics 21 2005 152 160
9. N. Cheng et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis Mol. Cancer Res. 1 2002 2 11
10. E.B. Pasquale Eph receptors and ephrins in cancer: bidirectional signalling and beyond Nat. Rev. Cancer 10 2010 165 180
11. J. Chen Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases Adv. Cancer Res. 114 2012 1 20
12. M. Kandouz The Eph/Ephrin family in cancer metastasis: communication at the service of invasion Cancer Metastasis Rev. 31 2012 353 373
13. A. Pandey et al. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis Science 268 1995 567 569
14. R.H. Adams et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis Genes Dev. 13 1999 295 306
15. S.S. Gerety et al. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development Mol. Cell 4 1999 403 414
16. S. Sawamiphack et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis Nature 465 2010 487 491
17. T. Mäkinen et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature Genes Dev. 19 2005 397 410
18. K. Alitalo et al. Lymphangiogenesis in development and human disease Nature 438 2005 946 953
19. T. Nomura et al. EphB signaling controls lineage plasticity of adult neural stem cell niche cells Cell Stem Cell 7 2010 730 743
20. H. Ji et al. Proteomic profiling of secretome and adherent plasma membranes from distinct mammary epithelial cell subpopulations Proteomics 11 2011 4029 4039
21. M. Genander et al. Ephrins negatively regulate cell proliferation in the epidermis and hair follicle Stem Cells (Dayton, OH) 28 2010 1196 1205
22. E. Binda et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas Cancer Cell 22 2012 765 780
23. N-Y. Yang et al. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells Cell. Signal. 23 2011 201 212
24. B.W. Day et al. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme Cancer Cell 23 2013 238 248
25. K. Khodosevich et al. EphA4 preserves postnatal and adult neural stem cells in an undifferentiated state in vivo J. Cell Sci. 124 2011 1268 1279
26. P.N. Lacor et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease J. Neurosci. 27 2007 796 807
27. J. Fabes et al. Regeneration-enhancing effects of EphA4 blocking peptide following corticospinal tract injury in adult rat spinal cord Eur. J. Neurosci. 26 2007 2496 2505
28. S. Parrinello et al. EphB signaling directs peripheral nerve regeneration through Sox2-dependent Schwann cell sorting Cell 143 2010 145 155
29. Y. Chen et al. Eph receptors at synapses: implications in neurodegenerative diseases Cell. Signal. 24 2012 606 611
30. B.K. Attwood et al. Ephs and ephrins: emerging therapeutic targets in neuropathology Int. J. Biochem. Cell Biol. 44 2012 578 581
31. A. Van Hoecke et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans Nat. Med. 18 2012 1418 1422
32. A.M. Simón et al. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease J. Alzheimers Dis. 17 2009 773 786
33. M. Cissé et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model Nature 469 2011 47 52
34. L. Lin et al. Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics Trends Neurosci. 32 2009 142 149
35. X. Jing et al. Ephrin-A1-mediated dopaminergic neurogenesis and angiogenesis in a rat model of Parkinson's disease PloS One 7 2012 e32019
36. M.A. Cercone et al. EphA2 receptor mediates increased vascular permeability in lung injury due to viral infection and hypoxia Am. J. Physiol. Lung Cell. Mol. Physiol. 297 2009 L856 L863
37. D. Pfaff et al. Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes J. Cell Sci. 121 2008 3842 3850
38. T. Kitamura et al. Enhancement of lymphocyte migration and cytokine production by ephrinB1 system in rheumatoid arthritis Am. J. Physiol. Cell Physiol. 294 2008 C189 C196
39. R.A. Sobel Ephrin A receptors and ligands in lesions and normal-appearing white matter in multiple sclerosis Brain Pathol. 15 2005 35 45
40. J.L. Dries et al. Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice J. Physiol. 589 2011 1725 1740
41. S.D. Funk et al. EphA2 activation promotes the endothelial cell inflammatory response: a potential role in atherosclerosis Arterioscler. Thromb. Vasc. Biol. 32 2012 686 695
42. S. Jellinghaus et al. Ephrin-A1/EphA4-mediated adhesion of monocytes to endothelial cells Biochim. Biophys. Acta 1833 2013 2201 2211
43. Y. Choi et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 19 2009 4467 4470
44. R. Jain et al. Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets Diabetologia 56 2013 1350 1355
45. A.S. Hahn et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma-associated herpesvirus Nat. Med. 18 2012 961 966
46. S. Chakraborty et al. Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection Proc. Natl. Acad. Sci. U.S.A. 109 2012 E1163 E1172
47. A.S. Hahn, and R.C. Desrosiers Rhesus monkey rhadinovirus uses Eph family receptors for entry into B cells and endothelial cells but not fibroblasts PLoS Pathog. 9 2013 e1003360
48. W. Chen et al. Hsp90 Inhibitors are efficacious against Kaposi sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins PLoS Pathog. 8 2012 e1003048
49. O.A. Negrete et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus Nature 436 2005 401 405
50. O.A. Negrete et al. Two key residues in EphrinB3 are critical for its use as an alternative receptor for Nipah virus PLoS Pathog. 2 2006 e7
51. K.N. Bossart et al. A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge Sci. Transl. Med. 3 2011 105ra103
52. K.N. Bossart et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection PLoS Pathog. 5 2009 e1000642
53. C. Giorgio et al. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation PloS One 6 2011 e18128
54. J. Jehle et al. Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid Br. J. Pharmacol. 167 2012 1563 1572
55. M. Tognolini et al. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor ChemMedChem 7 2012 1071 1083
56. M. Incerti et al. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor J. Med. Chem. 56 2013 2936 2947
57. R. Noberini et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors J. Biol. Chem. 283 2008 29461 29472
58. R. Noberini et al. A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors Chem. Biol. Drug Des. 78 2011 667 678
59. I.H. Mohamed et al. Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system Pharmacol. Res. 64 2011 464 470
60. R. Noberini et al. Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols Pharmacol. Res. 66 2012 363 373
61. M. Tognolini et al. Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites J. Agric. Food Chem. 60 2012 8877 8884
62. A. Petty et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo PloS One 7 2012 e42120
63. K. Lafleur et al. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4) J. Med. Chem. 52 2009 6433 6446
64. G. Martiny-Baron et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis Angiogenesis 13 2010 259 267
65. M.C. Pietanza et al. XL647 - a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib J. Thorac. Oncol. 7 2012 219 226
66. R. Noberini et al. Targeting Eph receptors with peptides and small molecules: progress and challenges Semin. Cell Dev. Biol. 23 2012 51 57
67. R. Noberini et al. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity PloS One 6 2011 e28611
68. B. Wu et al. HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery Chem. Biol. 20 2013 19 33
69. S. Duggineni et al. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4 Biochem. Pharmacol. 85 2013 507 513
70. C. Xiong et al. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide J. Nucl. Med. 52 2011 241 248
71. R. Zhang et al. Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts Biomaterials 32 2011 5872 5879
72. D. Djokovic et al. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis BMC Cancer 10 2010 641
73. M.A. Abéngozar et al. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth Blood 119 2012 4565 4576
74. V. Krasnoperov et al. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth Am. J. Pathol. 176 2010 2029 2038
75. D. Li et al. Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring Mol. Pharm. 10 2013 329 336
76. H. Ansuini et al. Anti-EphA2 antibodies with distinct in vitro properties have equal in vivo efficacy in pancreatic cancer J. Oncol. 2010 10.1155/2009/951917
77. K.T. Coffman et al. Differential EphA2 epitope display on normal versus malignant cells Cancer Res. 63 2003 7907 7912
78. C.M. Annunziata et al. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors Invest. New Drugs 31 2013 77 84
79. S. Wang et al. Targeted delivery of paclitaxel to EphA2-expressing cancer cells Clin. Cancer Res. 19 2013 128 137
80. H. Chen et al. A novel vaccine containing EphA2 epitope and LIGHT plasmid induces robust cellular immunity against glioma U251 cells Cell. Immunol. 272 2011 102 106
81. A. Conforti et al. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses J. Immunother. 32 2009 744 754